Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Finding offers potential new target for treatmentPsoriasis, a painful and uncomfortable inflammatory skin condition that ...

Opens in a new tab or window Should you see any of these where you apply your psoriasis medication, contact your dermatologist. Is treatment that you apply to the skin right for you? For this type ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

CLEVELAND—Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the activity of disease ...

Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...

20, 2025 — People with the skin condition psoriasis ... new research. These changes in the gut could explain why psoriasis sufferers often have ... Researchers Develop Nanofiber Patch for ...

Up to 1.5 million Britons suffer from the condition and doctors are hailing the new treatment as the most radical advance in psoriasis care for more than 20 years. Existing drugs can take several ...

Health Minister Ryan Park has rejected warnings from GPs, instead pushing ahead with plans to expand a range of medical ...

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter ...